Viewing Study NCT01661751


Ignite Creation Date: 2025-12-24 @ 11:46 PM
Ignite Modification Date: 2025-12-25 @ 9:39 PM
Study NCT ID: NCT01661751
Status: COMPLETED
Last Update Posted: 2012-08-09
First Post: 2012-08-03
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 003
Sponsor: Hualan Biological Engineering, Inc.
Organization:

Study Overview

Official Title: Phase III Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine
Status: COMPLETED
Status Verified Date: 2012-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The clinical trial was designed to evaluate the safety and immunogenicity against Group ACYW135 Meningococcal Polysaccharide Vaccine of Hualan administered on subjects 2 years of age and older.
Detailed Description: Complying with requirements of the approval letter of clinical trial issued by SFDA (Approval Letter No.: 2006L01017), Hualan conducted phase III clinical trial of Group ACYW135 Meningococcal Polysaccharide Vaccine to evaluate the safety and immunogenicity of the experimental vaccine.

The safety end points were the presence of any systemic, local and adverse reaction. Evaluation indicators of immunogenicity were bacteriocin levels of groups A, C, Y and W135 respectively in the serum after the whole vaccination.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
Hualanbio-phase III CT OTHER_GRANT Hualan Biological Engineering Inc. View